DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for hypochondroplasia — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHypochondroplasia maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hypochondroplasia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
fibroblast growth factor receptor 3 (FGFR3) — FGFR3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet acpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4K33 · 2.3405 Å · ligand PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER (ACP). Experimental structure, not a prediction.
What the evidence adds up to
Three patients with hypochondroplasia were described in 1978, with early recognition possible from abnormal body proportions including short limbs and lumbar lordosis, and without the facial features of achondroplasia. Two of those three patients had a large head. Radiological confirmation required a full skeletal survey.
A 2014 report described a 16-month-old male with a homozygous N540K mutation in the FGFR3 gene, a state not previously reported for hypochondroplasia. This patient showed a more severe phenotype than typical hypochondroplasia, representing an intermediate condition between achondroplasia and achondroplasia/hypochondroplasia compound heterozygosity. The case was considered important for genetic counselling when both parents have hypochondroplasia.
In 1985, two siblings of normal parents were described with a bone dysplasia syndrome resembling hypochondroplasia but distinguishable by subtle radiographic differences and an autosomal recessive inheritance pattern, unlike the autosomal dominant pattern of hypochondroplasia. The parents were 167.6 cm and 180.3 cm tall, and the two other children in the family had normal stature.
No drug treatment, clinical trial, or therapeutic intervention for hypochondroplasia appears in any of these abstracts. What is missing is any research into pharmacological treatment, any trial design, any patient stratification by genotype, and any funding directed toward therapy development for this condition.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Disease in Childhood · 1978 · 14 citations · open access
Hypochondroplasia.
AbstractClinical, radiological, and genetic features are described in 3 patients with hypochondroplasia. Early recognition of this disorder is possible from the abnormal body proportions with short limbs and lumbar lordosis without facial stigmata of achondroplasia. Radiological confirmation is possible provided a full skeletal survey is made. Two of our patients had a large head.
American Journal of Medical Genetics Part A · 2014 · 6 citations
Homozygous <i>N540K</i> hypochondroplasia—First report: Radiological and clinical features
AbstractWe describe a 16-month-old male with N540K homozygous mutation in the FGFR3 gene who showed a more severe phenotype than hypochondroplasia (HCH). To our knowledge, a homozygous state for this mutation causing HCH has not been reported before. The clinical and radiological characteristics of our patient represent an intermediate condition between achondroplasia and achondroplasia/hypochondroplasia compound heterozygosity. This case represents a new expression of FGFR3 spectrum and it is of considerable importance for the genetic counseling in cases where both parents are affected with HCH.
An Autosomal Recessive Bone Dysplasia Syndrome Resembling Hypochondroplasia
AbstractHypochondroplasia is an autosomal dominant skeletal dysplasia characterized by mild-to-moderate shortening of the limbs, a stocky build, lordosis, and occasionally mental deficiency.1-4 Hall and Spranger5 have recently defined distinct radiographic criteria for the diagnosis of this condition. We wish to describe two siblings of normal parents whose features are quite similar to those of individuals with hypochondroplasia. The characteristics that these siblings exhibited are distinguishable from hypochondroplasia by subtle radiographic differences as well as the differing inheritance pattern. The mother and father of these two girls are, respectively, 167.6 cm and 180.3 cm tall. The third and fourth children in this family, a girl and a boy, have normal stature.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
